Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease

Fernando Custodio Fervenza, Roser Torra, David G. Warnock

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Kidney involvement with progressive loss of kidney function (Fabry nephropathy) is an important complication of Fabry disease, an X-linked lysosomal storage disorder arising from deficiency of α-galactosidase activity. Clinical trials have shown that enzyme replacement therapy (ERT) with recombinant human α-galactosidase clears globotriaosylceramide from kidney cells, and can stabilize kidney function in patients with mild to moderate Fabry nephropathy. Recent trials show that patients with more advanced Fabry nephropathy and overt proteinuria do not respond as well to ERT alone, but can benefit from anti-proteinuric therapy given in conjunction with ERT. This review focuses on the use of enzyme replacement therapy with agalsidase-alfa and agalsidase-beta in adults with Fabry nephropathy. The current results are reviewed and evaluated. The issues of dosing of enzyme replacement therapy, the use of adjunctive agents to control urinary protein excretion, and the individual factors that affect disease severity are reviewed.

Original languageEnglish (US)
Pages (from-to)823-843
Number of pages21
JournalBiologics: Targets and Therapy
Volume2
Issue number4
StatePublished - 2008

Fingerprint

Enzyme Replacement Therapy
Fabry Disease
Safety
Galactosidases
Kidney
Proteinuria
Clinical Trials
Proteins

Keywords

  • Agalsidase
  • Anti-proteinuric therapy
  • Enzyme replacement therapy
  • Fabry nephropathy

ASJC Scopus subject areas

  • Oncology
  • Immunology and Allergy
  • Pharmacology (medical)
  • Gastroenterology
  • Rheumatology

Cite this

Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease. / Fervenza, Fernando Custodio; Torra, Roser; Warnock, David G.

In: Biologics: Targets and Therapy, Vol. 2, No. 4, 2008, p. 823-843.

Research output: Contribution to journalArticle

@article{be344518e2b941589e6848e59bfce2c9,
title = "Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease",
abstract = "Kidney involvement with progressive loss of kidney function (Fabry nephropathy) is an important complication of Fabry disease, an X-linked lysosomal storage disorder arising from deficiency of α-galactosidase activity. Clinical trials have shown that enzyme replacement therapy (ERT) with recombinant human α-galactosidase clears globotriaosylceramide from kidney cells, and can stabilize kidney function in patients with mild to moderate Fabry nephropathy. Recent trials show that patients with more advanced Fabry nephropathy and overt proteinuria do not respond as well to ERT alone, but can benefit from anti-proteinuric therapy given in conjunction with ERT. This review focuses on the use of enzyme replacement therapy with agalsidase-alfa and agalsidase-beta in adults with Fabry nephropathy. The current results are reviewed and evaluated. The issues of dosing of enzyme replacement therapy, the use of adjunctive agents to control urinary protein excretion, and the individual factors that affect disease severity are reviewed.",
keywords = "Agalsidase, Anti-proteinuric therapy, Enzyme replacement therapy, Fabry nephropathy",
author = "Fervenza, {Fernando Custodio} and Roser Torra and Warnock, {David G.}",
year = "2008",
language = "English (US)",
volume = "2",
pages = "823--843",
journal = "Biologics: Targets and Therapy",
issn = "1177-5475",
publisher = "Dove Medical Press Ltd.",
number = "4",

}

TY - JOUR

T1 - Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease

AU - Fervenza, Fernando Custodio

AU - Torra, Roser

AU - Warnock, David G.

PY - 2008

Y1 - 2008

N2 - Kidney involvement with progressive loss of kidney function (Fabry nephropathy) is an important complication of Fabry disease, an X-linked lysosomal storage disorder arising from deficiency of α-galactosidase activity. Clinical trials have shown that enzyme replacement therapy (ERT) with recombinant human α-galactosidase clears globotriaosylceramide from kidney cells, and can stabilize kidney function in patients with mild to moderate Fabry nephropathy. Recent trials show that patients with more advanced Fabry nephropathy and overt proteinuria do not respond as well to ERT alone, but can benefit from anti-proteinuric therapy given in conjunction with ERT. This review focuses on the use of enzyme replacement therapy with agalsidase-alfa and agalsidase-beta in adults with Fabry nephropathy. The current results are reviewed and evaluated. The issues of dosing of enzyme replacement therapy, the use of adjunctive agents to control urinary protein excretion, and the individual factors that affect disease severity are reviewed.

AB - Kidney involvement with progressive loss of kidney function (Fabry nephropathy) is an important complication of Fabry disease, an X-linked lysosomal storage disorder arising from deficiency of α-galactosidase activity. Clinical trials have shown that enzyme replacement therapy (ERT) with recombinant human α-galactosidase clears globotriaosylceramide from kidney cells, and can stabilize kidney function in patients with mild to moderate Fabry nephropathy. Recent trials show that patients with more advanced Fabry nephropathy and overt proteinuria do not respond as well to ERT alone, but can benefit from anti-proteinuric therapy given in conjunction with ERT. This review focuses on the use of enzyme replacement therapy with agalsidase-alfa and agalsidase-beta in adults with Fabry nephropathy. The current results are reviewed and evaluated. The issues of dosing of enzyme replacement therapy, the use of adjunctive agents to control urinary protein excretion, and the individual factors that affect disease severity are reviewed.

KW - Agalsidase

KW - Anti-proteinuric therapy

KW - Enzyme replacement therapy

KW - Fabry nephropathy

UR - http://www.scopus.com/inward/record.url?scp=67651096945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651096945&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 823

EP - 843

JO - Biologics: Targets and Therapy

JF - Biologics: Targets and Therapy

SN - 1177-5475

IS - 4

ER -